Ramipril

證據等級: L5

預測適應症: 10 個

Ramipril: From Hypertension to Pulmonary Hypertension with Unclear Multifactorial Mechanism

One-Sentence Summary

Ramipril is a long-established ACE inhibitor, classically used to treat hypertension and reduce cardiovascular risk. The TxGNN model predicts it may be effective for pulmonary hypertension with unclear multifactorial mechanism, but this direction currently has no supporting clinical trials and no supporting literature — the prediction stands on the model score alone.

Quick Overview

Item	Content
Original Indication	Hypertension (general ACE-inhibitor class knowledge; the evidence pack itself has no `original_indications` recorded)
Predicted New Indication	Pulmonary hypertension with unclear multifactorial mechanism
TxGNN Prediction Score	99.93%
Evidence Level	L5
New Zealand Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (original_moa: [Data Gap]). Based on general pharmacological knowledge, ramipril is a member of the ACE inhibitor class, which blocks conversion of angiotensin I to angiotensin II, lowering systemic vascular resistance and blood pressure. Its efficacy in hypertension and cardiovascular risk reduction is well established.

Pulmonary hypertension "with unclear multifactorial mechanism" corresponds to WHO Group 5 PH — a heterogeneous catch-all category (e.g., metabolic, haematologic, or systemic disorders) rather than a single well-defined pathway. Because RAAS activation can contribute to pulmonary vascular remodeling in some PH subtypes, an ACE inhibitor mechanism is not implausible in principle. However, Group 5 PH's mechanistic diversity makes a specific, reliable link to ACE inhibition speculative rather than established.

Critically, this is not corroborated by any external evidence in the pack: no clinical trials, no literature, and no ICTRP records were found for ramipril in this indication. The high TxGNN score alone should be read as a computational signal, not as confirmation of biological plausibility.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Safety Considerations

Please refer to the package insert for safety information.

(Note: safety.ddi.query_status is not_found, and TFDA/Medsafe package-insert warnings and contraindications are recorded as a Blocking data gap — DG001 — meaning safety cannot yet be formally assessed at Stage 1.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked predicted indication (pulmonary hypertension with unclear multifactorial mechanism) has zero clinical trial or literature support and is not marketed in New Zealand — this is a pure L5 model prediction with no independent evidence to act on.

To proceed, the following is needed:

TFDA/Medsafe package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
Confirmed mechanism of action data from DrugBank (DG002)
Formal original indication history for ramipril (not present in this evidence pack)
Targeted literature/trial search specifically on ramipril in WHO Group 5 pulmonary hypertension, since the general PubMed pull returned no hits

Additional note: other predictions in this evidence pack carry materially more evidence than the top rank — e.g., rank 8 (intracerebral hemorrhage, 4 literature incl. a ramipril-specific rat model study) and rank 10 (cerebral artery occlusion, 1 completed Phase 2 trial + 5 literature items directly involving ramipril). If further investigation is prioritized, these may warrant a separate evaluation ahead of the top-ranked pulmonary hypertension prediction.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.